Breaking News Instant updates and real-time market news.

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

, RHHBY

Roche

$30.82

1.72 (5.91%)

18:08
11/20/17
11/20
18:08
11/20/17
18:08

Deutsche cuts Bioverativ target to $53 after positive Roche data

Deutsche Bank analyst Andrew Peters lowered his price target for Bioverativ (BIVV) to $53 from $65 and remains cautious on the shares following today's positive data from Roche's (RHHBY) Phase 3 study evaluating Hemlibra in noninhibitor hemophilia A patients. While full data is needed to better understand the clinical and competitive profile, the data reported today suggest Hemlibra will likely pressure the longevity and sustainability of Bioverativ's Eloctate franchise, Peters told investors earlier in a research note. The analyst reiterated a Hold rating on Bioverativ shares. The stock closed the trading day down 9.5% to $50.76. Shire (SHPG), another company with a hemophilia franchise, closed today down 4% to $141.37 while Roche rallied 6% to $30.82.

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

RHHBY

Roche

$30.82

1.72 (5.91%)

SHPG

Shire

$141.37

-6 (-4.07%)

  • 30

    Nov

  • 09

    Dec

  • 23

    Dec

  • 23

    Feb

BIVV Bioverativ
$50.76

-5.35 (-9.53%)

11/20/17
PIPR
11/20/17
NO CHANGE
Target $71
PIPR
Overweight
Piper a buyer of Bioverativ on Roche study selloff
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Bioverativ (BIVV) after Roche (RHHBY) announced that its Haven 3 Phase III study met its primary endpoint. The analyst is waiting for the full data, expected in May, regarding absolute annualized bleed rates and consistency of effect. He remains confident in his forward estimates for Bioverativ's Eloctate and keeps an Overweight rating on the shares with a $71 price target. Absent full data detailing absolute annualized bleed rates for Roche's Hemlibra, it's difficult to draw too many conclusions on the relative efficacy compared to Eloctate in the non-inhibitor population, Raymond tells investors in a research note.
11/16/17
RBCM
11/16/17
NO CHANGE
RBCM
Top Pick
Roche approval neutral to slightly negative for Shire, says RBC Capital
RBC Capital analyst Douglas Miehm views the FDA approval for Roche's (RHHBY) Hemlibra as neutral to slight negative for Shire (SHPG). The approval comes three months early while the labeling for the hemophilia A drug contains a black box warning that severe blood clots may occur when Hemlibra is used with Feiba, Miehm tells investors in a research note. He believes investors will be "somewhat surprised" by the early timing of the approval but not surprised by the black box warning. He notes his estimates for Shire already reflect a 73% decline in inhibitor revenue from 2017 through 2025. Miehm keeps an Outperform rating on Shire. The stock in afternoon trading is up 5% to $146.66. Bioverativ (BIVV), another company with a hemophilia A treatment, is up 2% to $56.45.
10/27/17
PIPR
10/27/17
NO CHANGE
Target $71
PIPR
Overweight
Bioverativ selloff a 'golden' buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond contends that "nothing" on Bioverativ's earnings call would warrant the 7% selloff in the stock today and he believes a "misinterpretation" of the company's guidance may be the culprit. The fact that management did not update guidance and consensus is above the company's stated growth projection has caused some to interpret this as an implicit warning with respect to Q4 revenue, but Raymond doesn't think "management could have made it any clearer that Q417 expectations are safe." He recommends taking advantage of today's weakness and maintains an Overweight rating on Bioverativ shares with a $71 price target.
10/23/17
PIPR
10/23/17
INITIATION
Target $71
PIPR
Overweight
Bioverativ assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Bioverativ with an Overweight rating and increased price target of $71. The analyst views the valuation as compelling given the company's base business and "still-underappreciated upside" from recent acquisitions.
RHHBY Roche
$30.82

1.72 (5.91%)

11/20/17
BTIG
11/20/17
NO CHANGE
Target $242
BTIG
Buy
Shire selloff on Roche news seems overdone, says BTIG
BTIG analyst Timothy Chiang said today's weakness in Shire (SHPG) shares is overdone and creates a potential buying opportunity. While Roche's (RHBBY) emicizumab is likely to gain share at the expense of Shire's Advate, he does not expect a rapid conversion and thinks Shire's pipeline and platform seem overly discounted at current levels. Chiang has a Buy rating and $242 price target on Shire shares.
11/16/17
CANT
11/16/17
NO CHANGE
Target $222
CANT
Overweight
Roche's black box warning positive for Shire, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says the black box warning put on Roche's (RHHBY) Hemlibra by the FDA is a positive for Shire (SHPGY). The analyst believes the news supports her belief that concerns about competition for Shire's hemophilia franchise are overdone. Chen keeps an Overweight rating on Shire with a $222 price target. The stock in afternoon trading is up 4% to $146.13.
SHPG Shire
$141.37

-6 (-4.07%)

11/15/17
SUSQ
11/15/17
NO CHANGE
Target $225
SUSQ
Positive
Shire outlook remains underappreciated, says Susquehanna
Susquehanna analyst Andrew Finkelstein believes the outlook for Shire remain underappreciated. The analyst said the shares are trading at a low valuation and the company is well positioned for growth despite headwinds that are common across the sector. He sees growth accelerating and multiple levers to extend that runway. Finkelstein reiterated his Positive rating and $225 price target on Shire shares.

TODAY'S FREE FLY STORIES

STNG

Scorpio Tankers

$2.38

-0.01 (-0.42%)

06:27
04/25/18
04/25
06:27
04/25/18
06:27
Earnings
Scorpio Tankers reports Q1 adjusted EPS (10c), consensus (6c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

IPHI

Inphi

$31.46

1.1 (3.62%)

06:26
04/25/18
04/25
06:26
04/25/18
06:26
Recommendations
Inphi analyst commentary  »

Inphi price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

  • 29

    May

DDR

DDR Corp.

$6.68

0.025 (0.38%)

06:26
04/25/18
04/25
06:26
04/25/18
06:26
Upgrade
DDR Corp. rating change  »

DDR Corp. upgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$262.02

2.72 (1.05%)

06:25
04/25/18
04/25
06:25
04/25/18
06:25
Downgrade
Biogen rating change  »

Biogen downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 21

    May

  • 30

    May

EADSY

Airbus

, RYCEY

Rolls-Royce

06:24
04/25/18
04/25
06:24
04/25/18
06:24
Hot Stocks
Airbus, Rolls-Royce sign UltraFan engine integration collaboration agreement »

Airbus (EADSY) and…

EADSY

Airbus

RYCEY

Rolls-Royce

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVT

Avnet

$39.93

-0.99 (-2.42%)

06:24
04/25/18
04/25
06:24
04/25/18
06:24
Upgrade
Avnet rating change  »

Avnet upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

GOOG

Alphabet

$1,019.46

-48.24 (-4.52%)

, GOOGL

Alphabet Class A

$1,022.98

-50.08 (-4.67%)

06:23
04/25/18
04/25
06:23
04/25/18
06:23
Periodicals
Google will replace Google Play Music with YouTube Remix, Droid Life reports »

Google (GOOG, GOOGL) will…

GOOG

Alphabet

$1,019.46

-48.24 (-4.52%)

GOOGL

Alphabet Class A

$1,022.98

-50.08 (-4.67%)

SPOT

Spotify

$155.13

-2.96 (-1.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

, CMCSK

Comcast

06:23
04/25/18
04/25
06:23
04/25/18
06:23
Hot Stocks
Breaking Hot Stocks news story on Comcast, Comcast »

Comcast reports Q1 free…

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

PAGP

Plains GP Holdings

$25.02

-0.46 (-1.81%)

06:22
04/25/18
04/25
06:22
04/25/18
06:22
Downgrade
Plains GP Holdings rating change  »

Plains GP Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

GM

General Motors

$37.92

0.22 (0.58%)

06:22
04/25/18
04/25
06:22
04/25/18
06:22
Periodicals
General Motors, South Korea considering raising stake in GM Korea, Reuters says »

General Motors and the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 20

    Jun

AAPL

Apple

$162.87

-2.38 (-1.44%)

06:22
04/25/18
04/25
06:22
04/25/18
06:22
Periodicals
Apple CEO to meet President Trump on Wednesday, CNBC reports »

Apple CEO Tim Cook will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

, CMCSK

Comcast

06:21
04/25/18
04/25
06:21
04/25/18
06:21
Hot Stocks
Breaking Hot Stocks news story on Comcast, Comcast »

Comcast expects to…

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SPNE

SeaSpine

$11.16

-0.78 (-6.53%)

06:21
04/25/18
04/25
06:21
04/25/18
06:21
Conference/Events
SeaSpine management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 03

    May

OI

Owens-Illinois

$20.57

-1.19 (-5.47%)

06:21
04/25/18
04/25
06:21
04/25/18
06:21
Downgrade
Owens-Illinois rating change  »

Owens-Illinois downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

, CMCSK

Comcast

06:21
04/25/18
04/25
06:21
04/25/18
06:21
Hot Stocks
Comcast CEO says 'off to a great start in 2018' »

Brian L. Roberts,…

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

W

Wayfair

$68.76

-4.46 (-6.09%)

06:20
04/25/18
04/25
06:20
04/25/18
06:20
Recommendations
Wayfair analyst commentary  »

Wayfair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

PNC

PNC Financial

$145.00

-0.21 (-0.14%)

06:20
04/25/18
04/25
06:20
04/25/18
06:20
Conference/Events
PNC Financial management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 13

    Jul

  • 12

    Oct

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

, CMCSK

Comcast

06:20
04/25/18
04/25
06:20
04/25/18
06:20
Hot Stocks
Breaking Hot Stocks news story on Comcast, Comcast »

Comcast reports Q1…

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

PAA

Plains All American

$24.79

-0.42 (-1.67%)

06:20
04/25/18
04/25
06:20
04/25/18
06:20
Downgrade
Plains All American rating change  »

Plains All American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

AAPL

Apple

$162.87

-2.38 (-1.44%)

06:19
04/25/18
04/25
06:19
04/25/18
06:19
Periodicals
Apple reaches deal with Ireland to transfer $16B into escrow account, WSJ says »

In a step toward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

OGS

One Gas

$68.45

0.53 (0.78%)

06:18
04/25/18
04/25
06:18
04/25/18
06:18
Upgrade
One Gas rating change  »

One Gas upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 20

    May

  • 20

    May

  • 24

    May

  • 31

    Jul

  • 30

    Oct

PKOH

Park-Ohio

$37.85

-0.4 (-1.05%)

06:18
04/25/18
04/25
06:18
04/25/18
06:18
Conference/Events
Park-Ohio management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

CMCSA

Comcast

$33.34

-0.52 (-1.54%)

06:18
04/25/18
04/25
06:18
04/25/18
06:18
Earnings
Comcast reports Q1 adjusted EPS 62c, consensus 59c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

OVID

Ovid Therapeutics

$9.96

-0.09 (-0.90%)

06:17
04/25/18
04/25
06:17
04/25/18
06:17
Conference/Events
Ovid Therapeutics management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 08

    May

RUSHA

Rush Enterprises

$41.04

-1.96 (-4.56%)

06:17
04/25/18
04/25
06:17
04/25/18
06:17
Upgrade
Rush Enterprises rating change  »

Rush Enterprises upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.